Abbott Becomes Third US TAVR Competitor With Portico Approval
Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.
You may also be interested in...
September has been full of cardiovascular technology news, including announcements from Biotronik and Biosense Webster. Here are a few of the highlights.
The US FDA approved Abbott’s new Epic Plus stented tissue mitral valve and Epic Plus Supra stented tissue aortic valve.
June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.